The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Rapamycin treatment for amyotrophic lateral sclerosis: Protocol for a phase II randomized, double-blind, placebo-controlled, multicenter, clinical trial (RAP-ALS trial)
Open accessAbstract
INTRODUCTION: Misfolded aggregated proteins and neuroinflammation significantly contribute to amyotrophic lateral sclerosis (ALS) pathogenesis, hence representing therapeutic targets to modify disease expression. Rapamycin inhibits mechanistic target of Rapamycin (mTOR) pathway and enhances autophagy with demonstrated beneficial effects in neurodegeneration in cell line and animal models, improving phenotype in SQSTM1 zebrafish, in Drosophila model of ALS-TDP, and in the TDP43 mouse model, in which it reduced neuronal loss and TDP43 inclusions. Rapamycin also expands regulatory T lymphocytes (Treg) and increased Treg levels are associated with slow progression in ALS patients.Therefore, we planned a randomized clinical trial testing Rapamycin treatment in ALS patients. METHODS: RAP-ALS is a phase II randomized, double-blind, placebo-controlled, multicenter (8 ALS centers in Italy), clinical trial. The primary aim is to assess whether Rapamycin administration increases Tregs number in treated patients compared with control arm. Secondary aims include the assessment of safety and tolerability of Rapamycin in patients with ALS; the minimum dosage to have Rapamycin in cerebrospinal fluid; changes in immunological (activation and homing of T, B, NK cell subpopulations) and inflammatory markers, and on mTOR downstream pathway (S6RP phosphorylation); clinical activity (ALS Functional Rating Scale-Revised, survival, forced vital capacity); and quality of life (ALSAQ40 scale). DISCUSSION: Rapamycin potentially targets mechanisms at play in ALS (i.e., autophagy and neuroinflammation), with promising preclinical studies. It is an already approved drug, with known pharmacokinetics, already available and therefore with significant possibility of rapid translation to daily clinics. Findings will provide reliable data for further potential trials. ETHICS AND DISSEMINATION: The study protocol was approved by the Ethics Committee of Azienda Ospedaliero Universitaria of Modena and by the Ethics Committees of participating centers (Eudract n. 2016-002399-28) based on the Helsinki declaration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Autophagy induction using MTOR inhibitors is currently being tested in ALS – a phase II trial of rapamycin (sirolimus) for ALS patients began in 2018 [498].”
From Autophagy and ALS: mechanistic insights and therapeutic implications (2022) · cites this paper as [498]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Nalbandian, A., Llewellyn, K. J., Nguyen, C. C., Yazdi, P. G., & Kimonis, V. E. (2015) · PLoS ONE · doi:10.1371/journal.pone.0122888 · Cited by 89
RetractedEl Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis
Brooks, B. R., Miller, R. G., Swash, M., & Munsat, T. L. (2000) · Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders · doi:10.1080/146608200300079536 · Cited by 5,433
Autophagy and Viruses: Adversaries or Allies?
Dong, X., & Levine, B. (2013) · Journal of Innate Immunity · doi:10.1159/000346388 · Cited by 4,444
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., Flurkey, K., Nadon, N. L., Wilkinson, J. E., Frenkel, K., Carter, C. S., et al. (2009) · Nature · doi:10.1038/nature08221 · Cited by 3,766
Loss of autophagy in the central nervous system causes neurodegeneration in mice
Komatsu, M., Waguri, S., Chiba, T., Murata, S., Iwata, J.-I., Tanida, I., Ueno, T., Koike, M., Uchiyama, Y., Kominami, E., et al. (2006) · Nature · doi:10.1038/nature04723 · Cited by 3,500
Ravikumar, B., Vacher, C., Berger, Z., Davies, J. E., Luo, S., Oroz, L. G., Scaravilli, F., Easton, D. F., Duden, R., O'Kane, C. J., et al. (2004) · Nature Genetics · doi:10.1038/ng1362 · Cited by 2,347
Shi, C.-S., Shenderov, K., Huang, N.-N., Kabat, J., Abu-Asab, M., Fitzgerald, K. A., Sher, A., & Kehrl, J. H. (2012) · Nature Immunology · doi:10.1038/ni.2215 · Cited by 1,367
The EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis:, Andersen, P. M., Abrahams, S., Borasio, G. D., de Carvalho, M., Chio, A., Van Damme, P., Hardiman, O., Kollewe, K., Morrison, K. E., et al. (2012) · European Journal of Neurology · doi:10.1111/j.1468-1331.2011.03501.x · Cited by 1,117
Self-citationEfficacy and safety of sirolimus in lymphangioleiomyomatosis
McCormack, F. X., Inoue, Y., Moss, J., Singer, L. G., Strange, C., Nakata, K., Barker, A. F., Chapman, J. T., Brantly, M. L., Stocks, J. M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1100391 · Cited by 1,099
Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways
Cirulli, E. T., Lasseigne, B. N., Petrovski, S., Sapp, P. C., Dion, P. A., Leblond, C. S., Couthouis, J., Lu, Y.-F., Wang, Q., Krueger, B. J., et al. (2015) · Science · doi:10.1126/science.aaa3650 · Cited by 966
Cited by
Sorted by citations
Mizushima, N., & Levine, B. (2020) · New England Journal of Medicine · doi:10.1056/nejmra2022774 · Cited by 1,140
Molecular Mechanisms of TDP-43 Misfolding and Pathology in Amyotrophic Lateral Sclerosis
Prasad, A., Bharathi, V., Sivalingam, V., Girdhar, A., & Patel, B. K. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00025 · Cited by 817
Molecular mechanisms of cell death in neurological diseases
Moujalled, D., Strasser, A., & Liddell, J. R. (2021) · Cell Death & Differentiation · doi:10.1038/s41418-021-00814-y · Cited by 749
Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration
Querfurth, H., & Lee, H.-K. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00428-5 · Cited by 288
Innate Immune Cell Death in Neuroinflammation and Alzheimer’s Disease
Rajesh, Y., & Kanneganti, T. (2022) · Cells · doi:10.3390/cells11121885 · Cited by 269
Role of Nrf2 in aging, Alzheimer’s and other neurodegenerative diseases
George, M., Tharakan, M., Culberson, J. W., Reddy, A. P., & Reddy, P. H. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101756 · Cited by 216
Emerging roles of ATG7 in human health and disease
Collier, J. J., Suomi, F., Oláhová, M., McWilliams, T. G., & Taylor, R. W. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202114824 · Cited by 201
Autophagy and ALS: mechanistic insights and therapeutic implications
Chua, J. P., De Calbiac, H., Kabashi, E., & Barmada, S. J. (2022) · Autophagy · doi:10.1080/15548627.2021.1926656 · Cited by 189
Targeting autophagy, oxidative stress, and ER stress for neurodegenerative disease treatment
Esmaeili, Y., Yarjanli, Z., Paknia, F., Bidram, E., Łoś, M., Eshraghi, M., Klionsky, D. J., Ghavami, S., & Zarrabi, A. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.001 · Cited by 184
Silva, M. C., Nandi, G. A., Tentarelli, S., Gurrell, I. K., Jamier, T., Lucente, D., Dickerson, B. C., Brown, D. G., Brandon, N. J., & Haggarty, S. J. (2020) · Nature Communications · doi:10.1038/s41467-020-16984-1 · Cited by 157
Autophagy: a multifaceted player in the fate of sperm
Wang, M., Zeng, L., Su, P., Ma, L., Zhang, M., & Zhang, Y. (2021) · Human Reproduction Update · doi:10.1093/humupd/dmab043 · Cited by 155
Autophagy Activator Drugs: A New Opportunity in Neuroprotection from Misfolded Protein Toxicity
Thellung, S., Corsaro, A., Nizzari, M., Barbieri, F., & Florio, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040901 · Cited by 118
Disease-modifying therapies in amyotrophic lateral sclerosis
Chiò, A., Mazzini, L., & Mora, G. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.107986 · Cited by 123
Self-citationNeurofilaments in motor neuron disorders: towards promising diagnostic and prognostic biomarkers
Zucchi, E., Bonetto, V., Sorarú, G., Martinelli, I., Parchi, P., Liguori, R., & Mandrioli, J. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00406-3 · Cited by 112
Self-citationWang, Z., Liu, J., Zhu, Z., Su, C.-F., Sreenivasmurthy, S. G., Iyaswamy, A., Lu, J., Chen, G., Song, J., & Li, M. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110968 · Cited by 109
Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases
Xie, Z., Yang, X., Duan, Y., Han, J., & Liao, C. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01511 · Cited by 102
The Peripheral Immune System and Amyotrophic Lateral Sclerosis
McCombe, P., Lee, J. D., Woodruff, T. M., & Henderson, R. D. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00279 · Cited by 100
Targeting the nucleolus as a therapeutic strategy in human disease
Corman, A., Sirozh, O., Lafarga, V., & Fernández-Capetillo, Ó. (2022) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2022.09.006 · Cited by 89
Tauopathies: Deciphering Disease Mechanisms to Develop Effective Therapies
Silva, M. C., & Haggarty, S. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238948 · Cited by 89
The emerging role of metabolism in fibrosis
Henderson, J., & O’Reilly, S. (2021) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2021.05.003 · Cited by 87
The clinical trial landscape in amyotrophic lateral sclerosis—Past, present, and future
Wobst, H. J., Mack, K. L., Brown, D. G., Brandon, N. J., & Shorter, J. (2020) · Medicinal Research Reviews · doi:10.1002/med.21661 · Cited by 90
Proteotoxicity and Neurodegenerative Diseases
Ruz, C., Alcantud, J. L., Montero, F. V., Durán, R., & Bandrés‐Ciga, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165646 · Cited by 84
Bono, S., Feligioni, M., & Corbo, M. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00479-8 · Cited by 86
Jiang, J., Wang, Y., & Deng, M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1054006 · Cited by 88
Randomized, double-blind, placebo-controlled trial of rapamycin in amyotrophic lateral sclerosis
Mandrioli, J., D’Amico, R., Zucchi, E., Biasi, S. D., Banchelli, F., Martinelli, I., Simonini, C., Tartaro, D. L., Vicini, R., Fini, N., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40734-8 · Cited by 88
Self-citationSever, B., Ciftci, H. I., DeMi̇rci̇, H., Sever, H., Ocak, F., Yuluğ, B., Tateishi, H., Tateishi, T., Otsuka, M., Fujita, M., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052400 · Cited by 80
Mandrioli, J., Amedei, A., Cammarota, G., Niccolai, E., Zucchi, E., D’Amico, R., Ricci, F., Quaranta, G., Spanu, T., & Masucci, L. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01021 · Cited by 81
Self-citationProtective and Regenerative Roles of T Cells in Central Nervous System Disorders
Evans, F., Dittmer, M., de la Fuente, A. G., & Fitzgerald, D. C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02171 · Cited by 80
TDP-43 pathology: From noxious assembly to therapeutic removal
Keating, S. S., Gil, R. S., Swanson, M. E. V., Scotter, E. L., & Walker, A. K. (2022) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2022.102229 · Cited by 81
Subramanian, A., Tamilanban, T., Alsayari, A., Ramachawolran, G., Wong, L. S., Sekar, M., Gan, S. H., Subramaniyan, V., Chinni, S. V., Rani, N. N. I. M., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1094351 · Cited by 70
New Mechanisms and Targets of Subarachnoid Hemorrhage: A Focus on Mitochondria
Zhang, Z., Zhang, A., Liu, Y., Hu, X., Fang, Y., Wang, X., Luo, Y., Lenahan, C., & Chen, S. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666211101103646 · Cited by 62
Immune mechanisms and shared immune targets in neurodegenerative diseases
Weiner, H. L. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-01046-7 · Cited by 72
ALS and FTD: Where RNA metabolism meets protein quality control
Mandrioli, J., Mediani, L., Alberti, S., & Carra, S. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.06.003 · Cited by 63
Self-citationBlood biomarkers in ALS : challenges, applications and novel frontiers
Sturmey, E., & Malaspina, A. (2022) · Acta Neurologica Scandinavica · doi:10.1111/ane.13698 · Cited by 56
Rapamycin Responds to Alzheimer’s Disease: A Potential Translational Therapy
Hou, S.-J., Zhang, S., Li, Y., & Xu, S.-Y. (2023) · Clinical Interventions in Aging · doi:10.2147/cia.s429440 · Cited by 58
Interplay between immunity and amyotrophic lateral sclerosis: Clinical impact
Marchi, F. D., Munitić, I., Amedei, A., Berry, J. D., Feldman, E. L., Aronica, E., Nardo, G., Weehaeghe, D. V., Niccolai, E., Prtenjača, N., et al. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.06.027 · Cited by 52
Self-citationAmyotrophic Lateral Sclerosis and Other Motor Neuron Diseases
Quinn, C. C., & Elman, L. B. (2020) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000911 · Cited by 60
Trist, B. G., Fifita, J. A., Hogan, A. L., Grima, N., Smith, B. N., Troakes, C., Vance, C. A., Shaw, C. E., Al‐Sarraj, S., Blair, I. P., et al. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01421-9 · Cited by 53
Protein kinase inhibitors for amyotrophic lateral sclerosis therapy
Palomo, V., Nozal, V., Rojas‐Prats, E., Gil, C., & Martı́nez, A. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15221 · Cited by 51
Brown, D. G., Shorter, J., & Wobst, H. J. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.126942 · Cited by 53
Dysregulated autophagy as a new aspect of the molecular pathogenesis of Krabbe disease
Grosso, A. D., Angella, L., Tonazzini, I., Moscardini, A., Giordano, N., Caleo, M., Rocchiccioli, S., & Cecchini, M. G. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.05.011 · Cited by 47
FUS contributes to mTOR-dependent inhibition of translation
Sévigny, M., Bourdeau‐Julien, I., Venkatasubramani, J. P., Hui, J. B., Dutchak, P. A., & Sephton, C. F. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.013801 · Cited by 49
Prionoid Proteins in the Pathogenesis of Neurodegenerative Diseases
Wells, C., Brennan, S. E., Keon, M., & Saksena, N. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00271 · Cited by 46
Knowledge of PEP and PrEP among people living with HIV/aids in Brazil
Sousa, L. R. M., Elias, H. C., Fernandes, N. M., Gir, E., & Reis, R. K. (2021) · BMC Public Health · doi:10.1186/s12889-020-10135-3 · Cited by 43
Effect of natural leaf extracts as phytomedicine in curing geriatrics
Bhattacharya, T., Dey, P. S., Akter, R., Kabir, M. T., Rahman, M. H., & Rauf, A. (2021) · Experimental Gerontology · doi:10.1016/j.exger.2021.111352 · Cited by 45
Palma, J., Martinez, J., Vernetti, P. M., Ma, T., Perez, M. A., Zhong, J., Qian, Y., Dutta, S., Maina, K. N., Siddique, I., et al. (2022) · Movement Disorders · doi:10.1002/mds.28923 · Cited by 44
Cappella, M., Pradat, P., Querin, G., & Biferi, M. G. (2020) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-200531 · Cited by 42
Efficacy and safety of erythropoietin for traumatic brain injury
Liu, M., Wang, A. J., Chen, Y., Zhao, G., Jiang, Z., Wang, X., Shi, D., Zhang, T., Sun, B., He, H., et al. (2020) · BMC Neurology · doi:10.1186/s12883-020-01958-z · Cited by 37
A geroscience motivated approach to treat Alzheimer’s disease: Senolytics move to clinical trials
Gonzales, M. M., Krishnamurthy, S., Garbarino, V. R., Daeihagh, A. S., Gillispie, G. J., Deep, G., Craft, S., & Orr, M. E. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111589 · Cited by 37
Mitochondrial-targeted therapies in traumatic brain injury: From bench to bedside
Tabassum, S., Wu, S., Lee, C., Yang, B. S. K., Gusdon, A. M., Choi, H. A., & Ren, X. S. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00515 · Cited by 38
Multiple Facets of Autophagy and the Emerging Role of Alkylphosphocholines as Autophagy Modulators
Kaleağasıoğlu, F., Ali, D. M., & Berger, M. R. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00547 · Cited by 37
Soo, S. K., Rudich, P. D., Traa, A., Harris-Gauthier, N., Shields, H. J., & Raamsdonk, J. M. V. (2020) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2020.111297 · Cited by 37
Autophagy Dysfunction in ALS: from Transport to Protein Degradation
Cozzi, M., & Ferrari, V. (2022) · Journal of Molecular Neuroscience · doi:10.1007/s12031-022-02029-3 · Cited by 38
Krahn, A. I., Wells, C. I., Drewry, D. H., Beitel, L. K., Durcan, T. M., & Axtman, A. D. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00176 · Cited by 33
The contribution of multicellular model organisms to neuronal ceroid lipofuscinosis research
Huber, R. J., Hughes, S. M., Liu, W., Morgan, A., Tuxworth, R. I., & Russell, C. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.165614 · Cited by 34
Giovannelli, I., Heath, P. R., Shaw, P. J., & Kirby, J. (2020) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.1080/21678421.2020.1752246 · Cited by 39
Pharmacological Tools to Modulate Autophagy in Neurodegenerative Diseases
Suresh, S., Chakravorty, A., Giridharan, M., Garimella, L., & Manjithaya, R. R. (2020) · Journal of Molecular Biology · doi:10.1016/j.jmb.2020.02.023 · Cited by 34
Autophagy in ageing and ageing-related neurodegenerative diseases
Karabiyik, C., Frake, R. A., Park, S. J., Tanasa, M. P., & Rubinsztein, D. C. (2021) · Ageing and Neurodegenerative Diseases · doi:10.20517/and.2021.05 · Cited by 31
Liu, E., Karpf, L., & Bohl, D. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.767041 · Cited by 32
Therapeutic targeting of ALS pathways: Refocusing an incomplete picture
Maragakis, N. J., de Carvalho, M. A., & Weiss, M. D. (2023) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51887 · Cited by 31
Casiraghi, V., Sorce, M. N., Santangelo, S., Invernizzi, S., Bossolasco, P., Lattuada, C., Battaglia, C., Venturin, M., Silani, V., Colombrita, C., et al. (2024) · Experimental Neurology · doi:10.1016/j.expneurol.2024.115057 · Cited by 32
Novel therapeutic approaches to target neurodegeneration
de la Fuente, A. G., Pelucchi, S., Mertens, J., Luca, M. D., Mauceri, D., & Marcello, E. E. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16078 · Cited by 32
Rajabinejad, M., Ranjbar, S., Hezarkhani, L. A., Salari, F., Karaji, A. G., & Rezaiemanesh, A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.29401 · Cited by 29
Levite, M. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.357903 · Cited by 29
Status of ALS treatment, insights into therapeutic challenges and dilemmas
Khamaysa, M., & Pradat, P.-F. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12101601 · Cited by 28
ALS skin fibroblasts reveal oxidative stress and ERK1/2-mediated cytoplasmic localization of TDP-43
Romano, N., Catalani, A., Lattante, S., Belardo, A., Proietti, S., Bertini, L., Silvestri, F., Catalani, E., Cervia, D., Zolla, L., et al. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109591 · Cited by 30
Myotubularin-related phosphatase 5 is a critical determinant of autophagy in neurons
Chua, J. P., Bedi, K., Paulsen, M. T., Ljungman, M. E., Tank, E. M. H., Kim, E. S., McBride, J. P., Colon, J., Ward, M. E., Weisman, L. S., et al. (2022) · Current Biology · doi:10.1016/j.cub.2022.04.053 · Cited by 28
Proteostasis unbalance in prion diseases: Mechanisms of neurodegeneration and therapeutic targets
Thellung, S., Corsaro, A., Dellacasagrande, I., Nizzari, M., Zambito, M., & Florio, T. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.966019 · Cited by 26
Endogenous Mechanisms of Neuroprotection: To Boost or Not to Be
Marmolejo-Martínez-Artesero, S., Casas, C., & Romeo-Guitart, D. (2021) · Cells · doi:10.3390/cells10020370 · Cited by 28
Lastres‐Becker, I., Porras, G., Arribas-Blázquez, M., Maestro, I., Borrego‐Hernández, D., Boya, P., Cerdán, S., García‐Redondo, A., Martı́nez, A., & Martín‐Requero, Á. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063007 · Cited by 27
Stacchiotti, C., di Regnella, S. M., Cinotti, M., Spalloni, A., & Volpe, E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26083854 · Cited by 30
Wei, Y., Zhong, S., Yang, H., Wang, X., Lv, B., Bian, Y., Pei, Y., Xu, C., Zhao, Q., Yulan, W., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116496 · Cited by 28
Vila, O. F., Qu, Y., & Vunjak‐Novakovic, G. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1700225 · Cited by 25
Chaplot, K., Pimpale, L. G., Ramalingam, B., Deivasigamani, S., Kamat, S. S., & Ratnaparkhi, G. S. (2019) · Disease Models & Mechanisms · doi:10.1242/dmm.033803 · Cited by 22
Emerging Connections between Nuclear Pore Complex Homeostasis and ALS
Chandra, S., & Lusk, C. P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031329 · Cited by 21
Wang, X., Hu, W., Qu, L., Wang, J., Wu, A., Lo, H. H., Ng, J. P. L., Tang, Y., Yun, X., Wu, J., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106874 · Cited by 24
A mutant MATR3 mouse model to explain multisystem proteinopathy
Zhang, X., Yamashita, S., Hara, K., Doki, T., Tawara, N., Ikeda, T., Misumi, Y., Zhang, Z., Matsuo, Y., Nagai, M., et al. (2019) · The Journal of Pathology · doi:10.1002/path.5289 · Cited by 22
Pathogenic or protective? Neuropeptide Y in amyotrophic lateral sclerosis
Clark, C. M., Clark, R. M., Hoyle, J. A., & Dickson, T. C. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15125 · Cited by 20
In a search for efficient treatment for amyotrophic lateral sclerosis: Old drugs for new approaches
Kukharsky, M. S., Skvortsova, V. I., Бачурин, С. О., & Buchman, V. L. (2020) · Medicinal Research Reviews · doi:10.1002/med.21725 · Cited by 21
Analysis of shared underlying mechanism in neurodegenerative disease
Butler, R., Bradford, D. R., & Rodgers, K. E. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1006089 · Cited by 24
A microfluidic approach to rescue ALS motor neuron degeneration using rapamycin
Chennampally, P., Sayed-Zahid, A., Soundararajan, P., Sharp, J. C., Cox, G. A., Collins, S. D., & Smith, R. L. (2021) · Scientific Reports · doi:10.1038/s41598-021-97405-1 · Cited by 22
Molecular Basis of Neuronal Autophagy in Ageing: Insights from Caenorhabditis elegans
Konstantinidis, G., & Tavernarakis, N. (2021) · Cells · doi:10.3390/cells10030694 · Cited by 19
Zheng, C., Li, W., Ali, T., Peng, Z., Liu, J., Pan, Z., Feng, J., & Li, S. (2023) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-023-10068-9 · Cited by 17
Wang, X., Chen, W., Li, C., & Xu, R. (2024) · Reviews in the Neurosciences · doi:10.1515/revneuro-2024-0010 · Cited by 18
Wei, J., Liu, C., Qin, D., Ren, F., Duan, J., Chen, T., & Wu, A. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102544 · Cited by 15
Autophagy Contributes to the Rapamycin-Induced Improvement of Otitis Media
Xie, D., Zhao, T., Zhang, X., Kui, L., Wang, Q. L., Wu, Y., Zheng, T., Ma, P., Zhang, Y., Molteni, H., et al. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.753369 · Cited by 15
Therapeutic Targets in Amyotrophic Lateral Sclerosis: Focus on Ion Channels and Skeletal Muscle
Tarantino, N., Canfora, I., Camerino, G. M., & Pierno, S. (2022) · Cells · doi:10.3390/cells11030415 · Cited by 14
Emerging clinical investigational drugs for the treatment of amyotrophic lateral sclerosis
Martínez‐González, L., & Martı́nez, A. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2178416 · Cited by 12
He, X., Zhang, H., Zhang, T., Han, F., & Song, B. (2019) · Medicine · doi:10.1097/md.0000000000013957 · Cited by 11
Wang, Y., & Patani, R. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1805734 · Cited by 10
Aibara, N., Ohyama, K., Nakamura, M., Nakamura, H., Tamai, M., Kishikawa, N., Kawakami, A., Tsukamoto, K., Nakashima, M., & Kuroda, N. (2021) · Clinical & Experimental Immunology · doi:10.1111/cei.13588 · Cited by 9
Autophagy-related proteases accompany the transition of pre-chondrogenic cells into chondroblasts
Ramešová, A., Švandová, E., Veselá, B., Vacek, L., Lesot, H., & Matalová, E. (2021) · Annals of Anatomy - Anatomischer Anzeiger · doi:10.1016/j.aanat.2021.151781 · Cited by 9
Bastien, J., Menon, S., Messa, M., & Nyfeler, B. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.101018 · Cited by 9
The role of autophagy-lysosomal pathway in motor neuron diseases
Tedesco, B., Ferrari, V., Cozzi, M., Chierichetti, M., Casarotto, E., Pramaggiore, P., Mina, F., Piccolella, M., Cristofani, R., Crippa, V., et al. (2022) · Biochemical Society Transactions · doi:10.1042/bst20220778 · Cited by 8
Multiple ways to a dead end: diverse mechanisms by which ALS mutant genes induce cell death
Tsai, Y.-L., & Manley, J. L. (2021) · Cell Cycle · doi:10.1080/15384101.2021.1886661 · Cited by 8
The contribution of proteasomal impairment to autophagy activation by C9orf72 poly-GA aggregates
Pu, M., Tai, Y., Yuan, L., Zhang, Y., Guo, H., Hao, Z., Chen, J., Qi, X., Wang, G., Tao, Z., et al. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04518-5 · Cited by 11
A multiparametric activity profiling platform for neuron disease phenotyping and drug screening
Boivin, B., Roet, K. C. D., Huang, X., Karhohs, K. W., Rohban, M. H., Sandoe, J., Wiskow, O., Maeda, R. K., Grantham, A., Dornon, M. K., et al. (2021) · Molecular Biology of the Cell · doi:10.1091/mbc.e21-10-0481 · Cited by 7
Axon Injury-Induced Autophagy Activation Is Impaired in a C. elegans Model of Tauopathy
Ko, S. H., Gonzalez, G., Liu, Z., & Chen, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228559 · Cited by 5
Navigating the Autophagy Maze: ATG and Their Impact on Neurodegenerative Diseases
Amirian, R., Merati, A., Babamohamadi, M., Mirahmadi, Y., Esfahani, M. L., Rahmani, S., Izadi, Z., & Rezazadeh, D. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05332-3 · Cited by 4
Drug Screening and Validation Targeting TDP-43 Proteinopathy for Amyotrophic Lateral Sclerosis
Xin, J., Huang, S., Wen, J., Li, Y., Li, A., Satyanarayanan, S. K., Yao, X., & Su, H. (2024) · Aging and Disease · doi:10.14336/ad.2024.0440 · Cited by 4
Metadata
- Authors
- Mandrioli, J., D’Amico, R., Zucchi, E., Gessani, A., Fini, N., Fasano, A., Caponnetto, C., Chiò, A., Dalla Bella, E., Lunetta, C., Mazzini, L., Marinou, K., Sorarù, G., de Biasi, S., Lo Tartaro, D., Pinti, M., & Cossarizza, A.
- Affiliations
- University of Modena and Reggio Emilia (IT)
- Ospedale Policlinico San Martino (IT)
- Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT)
- Azienda Ospedaliero Universitaria Maggiore della Carita (IT)
- Corresponding author
- Mandrioli, Jessica
- ORCID
- Venue
- Medicine
- Published
- 2018-06
- Volume
- 97
- Issue
- 24
- Pages
- e11119
- ISSN
- 0025-7974 (ISSN-L)
- PMC
- PMC6024184
- OpenAlex
- W2807994366
- Cited by
- 128
- References
- 31
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 9 · 2023: 11 · 2022: 24 · 2021: 27 · 2020: 26 · 2019: 18
- FWCI
- 12.20
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, cc-by)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Padua Research Archive (University of Padova) (submittedVersion, cc-by)
- Funders
- Università Degli Studi di Modena e Reggio Emila
- Università degli Studi di Padova
- Università degli Studi di Torino
- Topics
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Keywords
- amyotrophic lateral sclerosis, rapamycin, mTOR signaling, autophagy, neuroinflammation, regulatory T cells, TDP-43, S6 phosphorylation, cerebrospinal fluid drug concentration, immunological markers, neurodegeneration, drug repurposing, ALS Functional Rating Scale, survival, forced vital capacity, quality of life
- MeSH terms
- Amyotrophic Lateral Sclerosis, Double-Blind Method, Humans, Immunosuppressive Agents, Italy, Quality of Life, Research Design, Biomarkers, Survival Rate, Treatment Outcome, Sirolimus, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
